Polymorphisms have been observed in this enzyme. A member of the Cytochrome P450 superfamily. Polymorphisms have been observed in this enzyme. A member of the Cytochrome P450 enzyme superfamily. An important polymorphism , as the drugs affected have a narrow therapeutic window, and low activity of this enzyme can lead to toxic side effects.
Drugs affected include debrisoquine and spartine.
Much interindividual variability exists among these Phase I DME's , but no polymorphisms yet pinpointed. A family of heme-containing monooxygenases performing oxidative reactions during drug and xenobiotic metabolism in the liver, lung and gut. Largely responsible for Phase I drug metabolism. Polymorphisms in these enzymes may lead to increase susceptibility to environmentally based diseases such as cancer. One of the most common polymorphisms , resulting in hemolysis upon exposure to oxidative drugs and foods, especially fava beans.